BOSTON, June 12 /PRNewswire/ -- Surface Logix Inc., a drug development
company using biophysical chemistry to create new small molecule drugs for
metabolic, vascular and inflammatory diseases, will present at the Pacific
Growth Equities 2006 Life Sciences Growth Conference. The presentation will
be given by Jim Mahoney, Surface Logix' President and Chief Executive
Officer, on June 14, 2006 at 10:30 a.m. ET from the InterContinental Mark
Hopkins Hotel in San Francisco.
In his presentation, Mr. Mahoney will provide an update on the
development pipeline including interim results from two clinical compounds;
SLx-2101, a second generation PDE5 inhibitor in Phase IIa for
cardiovascular disease, and Phase I results for SLx-4090, a first in class
MTP inhibitor targeting metabolic disorders including hypertriglyceridemia.
He will also give an overview of the preclinical data from the Rho Kinase
(ROCK) program. This program is focused on developing ROCK2 selective
compounds for inflammatory and fibrotic disease and a regulatory submission
is planned for the end of 2006.
About Surface Logix Inc.
Surface Logix Inc. uses its expertise in biophysical chemistry to
create new small molecule drugs that are optimized to meet the challenges
of human physiology. The company is advancing multiple internal programs
focused primarily on cardiovascular disease, oncology and metabolic
disorders and works with strategic partners to create differentiated new
chemical entities. For more information, please visit
http://www.surfacelogix.com.
Contact:
David H. Donabedian, Ph.D.
Vice President, Business Development
617.746.8520
Media:
Kari Watson
MacDougall Biomedical Communications Inc.
kwatson@macbiocom.com
508.647.0209
SOURCE Surface Logix Inc.
 back to top
Related links:
http://www.surfacelogix.com/
CONTACT:
David H. Donabedian, Ph.D., Vice President,
Business Development of Surface Logix Inc., +1-617-746-8520; or
Kari Watson of MacDougall Biomedical Communications Inc. for
Surface Logix Inc., kwatson@macbiocom.com, or +1-508-647-0209
|
